Fibrillar β-amyloid impairs the late phase of long term potentiation

Current Alzheimer Research

Volumn 3, Issue 3, 2006, Pages 179-183

  Puzzo, Daniela ^a   Arancio, Ottavio ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Physician and Surgeon Bldg ^*  (United States)

Author keywords

Alzheimer's disease; Amyloid; Fibrils; Synapse; Synaptic plasticity

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FIBER; HIPPOCAMPUS; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SYNAPTIC MEMBRANE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ELECTRIC STIMULATION; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; POLYMERS; PROTEIN STRUCTURE, SECONDARY; SYNAPTIC TRANSMISSION;

EID: 33745613783     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506777632871     Document Type: Article

References (57)

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17: 489-517 (1994).
2. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 10: 509-519 (1995).
3. Cullen W K, Suh YH, Anwyl R and Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8: 3213-3217 (1997).
4. Itoh A, Akaike T, Sokabe M, Nitta A, Iida R, Olariu A, et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur J Pharmacol 382: 167-175 (1999).
5. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O and Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99: 13217-21 (2002).
6. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539 (2002).
7. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8: 101-106 (1998).
8. Dobson CM. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356: 133-145 (2001).
9. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
10. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884 (1999).
11. Pillot T, Drouet B, Queille S, Labeur C, Vandekerchkhove J, Rosseneu M, et al. The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. J Neurochem 73: 1626-1634 (1999).
12. Monji A, Yoshida I, Tashiro K, Hayashi Y, Matsuda K and Tashiro N. Inhibition of A beta fibril formation and A beta-induced cytotoxicity by senile plaque-associated proteins. Neurosci Lett 278: 81-84 (2000).
13. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274: 25945-25952 (1999).
14. Goldberg MS and Lansbury PTJr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2: E115-9 (2000).
15. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE and Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97: 571-576 (2000).
16. Zhu YJ, Lin H and Lal R. Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AbetaP-channel-mediated cellular toxicity. FASEB J 14: 1244-1254 (2000).
17. Pike CJ, Walencewicz AJ, Glabe CG and Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563: 311-314 (1991).
18. Lorenzo A and Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91: 12243-12247 (1994).
19. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S,, et al. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 137: 676-682 (2002).
20. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, Agnaf OE et al. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25: 2455-2462 (2005).
21. Wang Q, Rowan MJ and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24: 6049-6056 (2004).
22. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
23. Stine WB Jr, Dahlgren KN, Krafft GA and LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622 (2003).
24. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2: 417-423 (2002).
25. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890 (1984).
26. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4: 2757-2763 (1985).
27. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
28. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325 (1992).
29. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359: 325-327 (1992).
30. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258: 126-129 (1992).
31. Busciglio J, Gabuzda DH, Matsudaira P and Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 90: 2092-2096 (1993).
32. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924: 17-25 (2000).
33. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 87: 1561-1565 (1990).
34. Yamazaki T, Selkoe DJ and Koo EH. Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol 129: 431-442 (1995).
35. Yankner BA and Mesulam MM. Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 325: 1849-1857 (1991).
36. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM and Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55: 801-814 (2004).
37. Larson J, Lynch G, Games D and Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840: 23-35 (1999).
38. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 3228-3233 (1999).
39. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
40. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
41. Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21: 4691-4698 (2001).
42. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483-6492 (1999).
43. Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387: 500-505 (1997).
44. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-452 (2004).
45. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19: 597-598 (2005).
46. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23: 4096-4105 (2004).
47. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH and Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-4133 (2001).
48. Saleshando G and O'Connor JJ. SB203580, the p38 mitogena-ctivated protein kinase inhibitor blocks the inhibitory effect of beta-amyloid on long-term potentiation in the rat hippocampus. Neurosci Lett 288: 119-22 (2000).
49. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A and Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25: 6887-97 (2005).
50. Zhao D, Watson JB and Xie CW. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 92: 2853-2858 (2004).
51. Huang YY, Li XC and Kandel ER. cAMP contributes to mossy fiber LTP by initiating both a covalently mediated early phase and macromolecular synthesis-dependent late phase. Cell 79: 69-79 (1994).
52. Weisskopf MG, Castillo PE, Zalutsky RA and Nicoll RA. Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science 265: 1878-1882 (1994).
53. Kanterewicz BI, Urban NN, McMahon DB, Norman ED, Giffen LJ, Favata MF, et al. The extracellular signal-regulated kinase cascade is required for NMDA receptor-independent LTP in area CA1 but not area CA3 of the hippocampus. J Neurosci 20: 3057-3066 (2000).
54. Frey U, Huang YY and Kandel ER. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260: 1661-1664 (1993).
55. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511 (2002).
56. Nakagami Y, Nishimura S, Murasugi T, Kubo T, Kaneko I, Meguro M, et al. A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. Eur J Pharmacol 457: 11-17 (2002).
57. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556-561 (2005).